AZD0466 shows dose-dependent transient thrombocytopenia, and on target toxicity for Bcl-xL however this can be mitigated via a weekly dosing schedule which allows for platelet recovery between doses (Fig. 7d). This evidence concerns the gene BCL2L1 and Thrombocytopenia.